What role is precision medicine playing in transforming cancer treatment — and how are developers adapting?
In the latest Pharma’s Almanac commentary, Director of Business Strategy Seahee Kim shares her expert insights on advancing precision medicine strategies in oncology through patient-derived organoids (PDO) services.
By providing a clinically relevant evaluation of drug efficacy and toxicity, organoids preserve tumor heterogeneity and structural complexity. Samsung Organoids, our PDO-based drug screening services, help elucidate the mechanistic relevance of drug responses.
In the latest Pharma’s Almanac commentary, Director of Business Strategy Seahee Kim shares her expert insights on advancing precision medicine strategies in oncology through patient-derived organoids (PDO) services.
By providing a clinically relevant evaluation of drug efficacy and toxicity, organoids preserve tumor heterogeneity and structural complexity. Samsung Organoids, our PDO-based drug screening services, help elucidate the mechanistic relevance of drug responses.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article